Divergent Genetic Architectures in Multiple Sclerosis: Why Disease Susceptibility Does Not Predict Disease Severity
The reviewed article, Contrasting genetic architectures of multiple sclerosis susceptibility and outcome phenotypes, addresses a central problem in contemporary multiple sclerosis (MS) research: why patients with the same diagnosis can experience profoundly different long-term clinical trajectories. The authors argue that the genetic architecture underlying MS susceptibility is not necessarily the same as the architecture governing disability progression, neurodegeneration, imaging changes, or therapeutic response. This distinction is scientifically important because much of MS genetics over the last two decades has focused on identifying variants that increase disease risk, particularly within immune pathways. The article therefore shifts the discussion from “who develops MS?” to the more clinically pressing question of “what determines how severe MS becomes after onset?”
Susceptibility Genetics: Strong Signals, Primarily Immunological
One of the article’s major strengths is its clear synthesis of what is already well established in MS genetics. More than 200 common variants have been linked to MS susceptibility, with the strongest effects concentrated in the major histocompatibility complex, especially the HLA-DRB1*15:01 allele. These discoveries have confirmed that MS is highly polygenic and that immune-cell biology plays a dominant role in disease initiation. The review also notes that common variants explain only part of the heritable liability, indicating that much of the genetic contribution remains unresolved. Nevertheless, susceptibility loci have already informed risk modeling, causal inference for exposures such as vitamin D deficiency and obesity, and drug-target prioritization. This body of work has been transformative, but the article emphasizes that its translational value for patients with established disease may be limited if risk variants do not also shape progression.
Age at Onset Versus Disease Severity: An Important Divergence
The article identifies age at onset as one of the few outcome-related traits that does show meaningful overlap with susceptibility genetics. Individuals carrying a higher burden of MS risk alleles, including HLA-DRB1*15:01, tend to develop the disease earlier, which is consistent with a liability-threshold model in which greater inherited risk accelerates crossing into clinical disease. However, this overlap does not extend convincingly to long-term disability outcomes. Meta-analyses and large cohort studies reviewed in the paper generally show weak, inconsistent, or absent associations between established MS risk variants and clinical severity measures such as the Expanded Disability Status Scale and the MS Severity Score. This is one of the review’s most consequential conclusions: the genetics of disease onset and the genetics of disease worsening appear to be at least partly distinct.
Neuroimaging and Retinal Phenotypes: Mixed Evidence from Intermediate Biomarkers
The article then turns to neuroimaging and retinal measures, which are often considered more sensitive or biologically proximal indicators of tissue damage than clinical disability scales alone. Studies of MRI outcomes, such as lesion burden and brain atrophy, have yielded inconsistent findings when examined in relation to susceptibility variants. Some long-term longitudinal cohorts suggest that certain risk alleles may be associated with faster atrophy or lesion accumulation, whereas shorter clinical-trial datasets frequently fail to detect such effects. The same general pattern emerges for retinal biomarkers assessed by optical coherence tomography. Importantly, the review highlights that these discrepancies may reflect methodological limitations, including short follow-up, heterogeneous imaging pipelines, and insufficient power. The figure on page 5 is especially informative: it contrasts tissue-specific heritability enrichment and shows susceptibility associated with immune and lymphoid tissues, whereas severity is enriched in central nervous system tissues, underscoring a biologically meaningful separation between onset and progression.
Direct Studies of Severity Genetics: Evidence for a Distinct CNS-Centered Architecture
A particularly significant contribution discussed in the review is the emergence of genome-wide association studies that examine MS severity directly rather than testing known susceptibility variants secondarily. In the large multicenter study summarized by the authors, common genetic variation accounted for a measurable proportion of long-term disability variance, and severity-associated heritability was enriched specifically in central nervous system tissues rather than immune compartments. The lead genome-wide significant association identified at rs10191329 in the DYSF–ZNF638 locus did not associate with MS susceptibility, which strongly supports the idea of partially separate genetic architectures. Moreover, this variant was linked to faster disability accumulation, earlier need for walking assistance, greater rates of brain and retinal atrophy, elevated neurofilament light levels, and more destructive neuropathological features. Collectively, these observations suggest that progression genetics may be tied more closely to neuroaxonal injury, chronic inflammation within the CNS, and tissue resilience than to the immune mechanisms driving disease onset.
Pharmacogenetics and Therapeutic Implications
The article also explores how genetic profiling may eventually inform treatment selection. While MS has not yet reached the level of pharmacogenetic implementation seen in some other fields, the review describes examples that illustrate its potential. A variant associated with interferon-β-induced liver injury demonstrated strong risk elevation, although its clinical relevance declined as treatment paradigms changed. More recently, HLA-A*03:01 has been implicated in differential response to glatiramer acetate versus interferon-β, suggesting that host immunogenetic background may influence therapeutic efficacy in a subset of patients. These findings remain preliminary in translational terms, but they point toward a future in which treatment decisions may be informed not only by disease phenotype and imaging but also by genotype. The broader implication is that therapeutics developed from susceptibility genetics may not automatically address progression biology, and precision medicine in MS will require genetic frameworks tailored specifically to outcome phenotypes.
Conclusion: Toward a New Framework for MS Heterogeneity
In conclusion, this article makes a compelling case that MS should not be treated as a genetically uniform disease across all stages and phenotypes. The traditional focus on susceptibility has yielded profound insights into immune-mediated disease initiation, but long-term outcomes appear to depend on additional and partly distinct mechanisms involving CNS vulnerability, repair failure, and neurodegeneration. The review therefore advocates a conceptual shift: instead of assuming that genes influencing MS risk will also govern severity, researchers should directly interrogate progression, imaging trajectories, retinal biomarkers, and treatment response. This perspective has major implications for biomarker discovery, therapeutic development, and patient stratification. Ultimately, the authors present MS as a biologically heterogeneous disorder whose future classification may depend on integrating genetics, environment, comorbidities, and quantitative biomarkers into mechanism-based subgroups rather than relying on a single measure of disability.
Disclaimer: This blog post is based on the provided research article and is intended for informational purposes only. It is not intended to provide medical advice. Please consult with a healthcare professional for any health concerns.
References:
Sorella, M. Y., Ding, Y., Garcia, A. M., Ygonia, M., Wang, L., Jacobs, B. M., & Harroud, A. (2026). Contrasting genetic architectures of multiple sclerosis susceptibility and outcome phenotypes. Revue neurologique, S0035-3787(26)00500-X. Advance online publication. https://doi.org/10.1016/j.neurol.2026.03.007
